Dutescu Ilinca A, Hillier Sean A
School of Health Policy & Management, Faculty of Health, York University, Toronto, ON, Canada.
Infect Drug Resist. 2021 Feb 5;14:415-434. doi: 10.2147/IDR.S287792. eCollection 2021.
Antibiotic resistance is an urgent public health threat that has received substantial attention from the world's leading health agencies and national governmental bodies alike. However, despite increasing rates of antibiotic resistance, pharmaceutical companies are reluctant to develop new antibiotics due to scientific, regulatory, and financial barriers. Nonetheless, only a handful of countries have addressed this by implementing or proposing financial incentive models to promote antibiotic innovation. This study is comprised of a systematic review that aimed to understand which antibiotic incentive strategies are most recommended within the literature and subsequently analyzed these incentives to determine which are most likely to sustainably revitalize the antibiotic pipeline. Through a case study of Canada, we apply our incentive analysis to the Canadian landscape to provide decision-makers with a possible path forward. Based on our findings, we propose that Canada support the ongoing efforts of other countries by implementing a fully delinked subscription-based market entry reward. This paper seeks to spark action in Canada by shifting the national paradigm to one where antibiotic research and development is prioritized as a key element to addressing antibiotic resistance.
抗生素耐药性是一个紧迫的公共卫生威胁，已受到全球主要卫生机构和各国政府机构的高度关注。然而，尽管抗生素耐药率不断上升，但由于科学、监管和资金方面的障碍，制药公司仍不愿研发新的抗生素。尽管如此，只有少数国家通过实施或提议财政激励模式来促进抗生素创新，从而解决了这一问题。本研究包括一项系统综述，旨在了解文献中最推荐的抗生素激励策略，随后对这些激励措施进行分析，以确定哪些措施最有可能可持续地振兴抗生素研发渠道。通过对加拿大的案例研究，我们将激励分析应用于加拿大的情况，为决策者提供一条可能的前进道路。基于我们的研究结果，我们建议加拿大通过实施完全脱钩的基于订阅的市场准入奖励来支持其他国家正在进行的努力。本文旨在通过将国家范式转变为将抗生素研发作为应对抗生素耐药性的关键要素加以优先考虑，从而在加拿大引发行动。
